Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 9Male Urogenital Diseases 3Prostatic Intraepithelial Neoplasia 2Uremia 1Neoplasm Metastasis 1Disease Progression 1Colorectal Cancer Metastatic 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 37Gemcitabine 29Nivolumab 20Cisplatin 19atezolizumab 15avelumab 14Docetaxel 13enfortumab vedotin 10Carboplatin 10durvalumab 9Magnetic Resonance Spectroscopy 9Ipilimumab 8Paclitaxel 7Pemetrexed 6toripalimab 5cabozantinib 5Fluorodeoxyglucose F18 5sacituzumab govitecan 4cabazitaxel 4Taxes 4vinflunine 3tremelimumab 3pemigatinib 3X-Rays 3Standard of Care 3Specimen Handling 3Radiotherapy 3Mitomycin 3Immunotherapy 3Immunoglobulin G 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Transitional Cell × Lycopene × Clear all
NCT00172367 2008-09-26

Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

National Taiwan University Hospital

Phase 2 Withdrawn
80 enrolled
Genitourinary

Carcinoma, Transitional Cell, Uremia, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡